Ixekizumab 伊西贝单抗; LY2439821,98.90%

产品编号:Bellancom-P9924| CAS NO:1143503-69-8

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-P9924
2600.00 杭州 北京(现货)
Bellancom-P9924
6800.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

Ixekizumab 伊西贝单抗; LY2439821

产品介绍 Ixekizumab 是一种人源化 IgG4 单克隆抗体,可选择性结合和中和白细胞介素 IL-17A (KD<3 pM)。Ixekizumab 直接阻断IL-17A与IL-17RA的结合,但不与其他IL-17家族成员结合。Ixekizumab 用于中重度斑块型银屑病的研究。
生物活性

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis.

体外研究

The equilibrium KD of Ixekizumab for human and cynomolgus monkey IL-17A were 1.8 pM and 0.8 pM, respectively. Ixekizumab also bound to rabbit IL-17A, but the affinity was lower, and the binding was heterogeneous (KD of 1.3 nM and 14 nM). Ixekizumab shows no binding to either mouse or rat IL-17A.
Ixekizumab (0.1-10000 pM) inhibits human IL-17A- or human IL-17A/F heterodimer-induced growth-regulated oncogene (GRO)α secretion from HT-29 cells in a dose-dependent fashion. Ixekizumab inhibits cynomolgus monkey IL-17A-induced GROα secretion from HT-29 cells in a dose-dependent fashion.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Ixekizumab (0.001-1 mg/kg; i.v.) is able to decrease human IL-17A-induced keratinocyte chemoattractant (KC) secretion in the plasma of the C57BL/6 mice in a dose-dependent manner.
In male cynomolgus monkeys, following IV administration of 1 mg/kg, Ixekizumab is eliminated with a mean half-life of 6.5 days. After SC administration of 1 mg/kg, Ixekizumab reaches an average maximal plasma concentration of 11.1 µg/mL ~72 hours postdose. The mean elimination half-life following the SC injection was 10.3 days.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice (n=5 per group, 8-12-week old, subcutaneous injection of human IL-17A)
Dosage: 1 mg/kg, 0.1 mg/kg, 0.01 mg/kg, or 0.001 mg/kg (corresponding to 20 µg, 2 µg, 0.2 µg, and 0.02 µg per mouse, respectively)
Administration: I.v.; 1 hour prior to a subcutaneous (SC) injection of human IL-17A
Result: Decrease human IL-17A-induced KC secretion in the plasma of the C57BL/6 mice in a dose-dependent manner.
体内研究

Ixekizumab (0.001-1 mg/kg; i.v.) is able to decrease human IL-17A-induced keratinocyte chemoattractant (KC) secretion in the plasma of the C57BL/6 mice in a dose-dependent manner.
In male cynomolgus monkeys, following IV administration of 1 mg/kg, Ixekizumab is eliminated with a mean half-life of 6.5 days. After SC administration of 1 mg/kg, Ixekizumab reaches an average maximal plasma concentration of 11.1 µg/mL ~72 hours postdose. The mean elimination half-life following the SC injection was 10.3 days.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice (n=5 per group, 8-12-week old, subcutaneous injection of human IL-17A)
Dosage: 1 mg/kg, 0.1 mg/kg, 0.01 mg/kg, or 0.001 mg/kg (corresponding to 20 µg, 2 µg, 0.2 µg, and 0.02 µg per mouse, respectively)
Administration: I.v.; 1 hour prior to a subcutaneous (SC) injection of human IL-17A
Result: Decrease human IL-17A-induced KC secretion in the plasma of the C57BL/6 mice in a dose-dependent manner.
性状Liquid
溶解性数据
运输条件
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服